Thomas Leggett Sells 2,382 Shares of Stoke Therapeutics (NASDAQ:STOK) Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) CFO Thomas Leggett sold 2,382 shares of the company’s stock in a transaction on Wednesday, March 18th. The shares were sold at an average price of $31.34, for a total transaction of $74,651.88. Following the completion of the transaction, the chief financial officer owned 10,172 shares of the company’s stock, valued at $318,790.48. This represents a 18.97% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Thomas Leggett also recently made the following trade(s):

• On Tuesday, March 17th, Thomas Leggett sold 2,196 shares of Stoke Therapeutics stock. The stock was sold at an average price of $33.01, for a total value of $72,489.96.

Stoke Therapeutics Stock Performance

Stoke Therapeutics stock opened at $33.51 on Friday. Stoke Therapeutics, Inc. has a fifty-two week low of $5.35 and a fifty-two week high of $40.22. The company has a market capitalization of $1.98 billion, a P/E ratio of 50.01 and a beta of 1.07. The stock has a 50-day simple moving average of $32.61 and a 200-day simple moving average of $30.02.

Institutional Trading of Stoke Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Stoke Therapeutics by 5.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,167 shares of the company’s stock valued at $162,000 after purchasing an additional 1,149 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Stoke Therapeutics by 21.4% in the first quarter. Goldman Sachs Group Inc. now owns 1,662,039 shares of the company’s stock valued at $11,053,000 after purchasing an additional 293,072 shares during the period. Jane Street Group LLC raised its stake in shares of Stoke Therapeutics by 125.2% during the first quarter. Jane Street Group LLC now owns 26,978 shares of the company’s stock worth $179,000 after purchasing an additional 15,001 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Stoke Therapeutics by 7.9% during the second quarter. Geode Capital Management LLC now owns 972,921 shares of the company’s stock worth $11,044,000 after purchasing an additional 70,935 shares during the period. Finally, Police & Firemen s Retirement System of New Jersey lifted its holdings in shares of Stoke Therapeutics by 33.2% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 9,558 shares of the company’s stock worth $108,000 after purchasing an additional 2,384 shares during the period.

Stoke Therapeutics News Summary

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Canaccord raised its price target sharply to $60 and assigned a Buy, giving STOK a meaningful upside projection versus recent levels — a clear catalyst for buying interest. Canaccord raises STOK price target to $60 (Benzinga)
• Positive Sentiment: Other analysts reiterated/raised Buy views and targets (BTIG reaffirmed Buy with a $39 target; Wedbush pushed its target to $38; Needham published a bullish outlook), adding breadth to the bullish narrative and likely attracting momentum and institutional buyers. BTIG reaffirmation (Benzinga) Wedbush boosts price target to $38 (AmericanBankingNews) Needham bullish outlook (AmericanBankingNews)
• Positive Sentiment: Coverage of Stoke’s STK‑001 program emphasizes potential beyond seizure reduction (aiming to restore developmental loss in Dravet syndrome), supporting longer‑term upside expectations if clinical data meet endpoints. FierceBiotech: Stoke aims to restore developmental loss in Dravet syndrome
• Neutral Sentiment: Analysis pieces reviewed a recent sharp pullback and what triggered it—useful context for traders but not a new company catalyst. Kalkine: What triggered the sudden drop?
• Neutral Sentiment: Technical/volume note — today’s volume is well above average and the stock is trading above both its 50‑ and 200‑day SMAs, indicating higher investor interest; this can amplify moves in either direction.
• Negative Sentiment: Significant insider selling: multiple executives (including the CFO, general counsel and senior insiders such as Barry Ticho) disclosed sizable sales across March 17–19, which can weigh on sentiment and prompt investor caution despite analyst optimism. Representative SEC filings: SEC Form 4 (Jonathan Allan) SEC Form 4 (Barry Ticho)

Analysts Set New Price Targets

STOK has been the subject of a number of research reports. Wolfe Research initiated coverage on Stoke Therapeutics in a research note on Monday, February 23rd. They issued an “outperform” rating and a $40.00 price objective for the company. Wedbush raised their target price on shares of Stoke Therapeutics from $36.00 to $38.00 and gave the stock an “outperform” rating in a research report on Tuesday. Loop Capital set a $35.00 target price on shares of Stoke Therapeutics in a report on Monday, January 5th. BTIG Research reiterated a “buy” rating and issued a $39.00 price target on shares of Stoke Therapeutics in a research report on Thursday. Finally, Guggenheim initiated coverage on shares of Stoke Therapeutics in a research note on Thursday, February 5th. They set a “buy” rating and a $60.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $41.83.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.